

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

ART UNIT: 1626

EL 983153960 US Express Mail Label Number

May 25, 2006 Date of Deposit

EXAMINER: FREISTEIN, ANDREW B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF DONALD PINTO, ET AL.

APPLICATION NO: 10/801518

العادي العا

FILED: 03/16/2004

FOR: SULFONYL-AMIDINO-CONTAINING AND TETRAHYDROPYRIMIDINO-CONTAINING

COMPOUNDS AS FACTOR Xa INHIBITORS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s) and charge the appropriate fee of \$180 under §1.17 (p) to Deposit Account 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is here enclosed.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Attorney for Applicant Reg. No. 45,914

G. Sún, Ph.D.

Phone: 609-252-3791

Date: May 25, 2006

05/30/2006 WABDELR1 00000033 193880 10801518

02 FC:1806

180.00 DA

MAY 2.5 2006
Substitute for form 1449/P

PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

COMPLETE IF KNOWN Application Number 10/801,518 Filing Date 3/16/2004 First Named Inventor DONALD J. PINTO Art Unit 1626 Examiner Name FREISTEIN, ANDREW B. Attorney Docket Number PH 7466 NP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

Sheet 1 Of 1

Officer		OI I	
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Bauer, K.A., "Fondaparinux: a new synthetic and selective inhibitor of Factor Xa", Best Practice & Research Clinical Haematology, Vol. 17, No. 1, pp. 89-104, 2004.	
	AB	Elodi et al., "Optimization of Conditions for the Catalytic Effect of The Factor IXa – Factor VIII Complex: Probable role of the complex in the amplification of blood coagulation", Thrombosis Research, Vol. 15, pp. 617-623, 1979.	
	AC	Gresele et al., "Novel approaches to the treatment of thrombosis", TRENDS in Pharmacological Sciences, Vol. 23, No. 1, pp. 25-32, Jan 2002.	
·	AD	Kaiser, B., "Visions & Reflections – Factor Xa – a promising target for drug development", Cell. Mol. Life Sci., Vol. 59, pp. 189-192, 2002.	
	AE	Linkins et al., "New Anticoagulants", Seminars in Thrombosis and Hemostasis, Vol. 29, No. 6, pp. 619-631, 2003.	
	AF	Rauch et al., "Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences", Annals of Internal Medicine, Vol. 134, No. 3., pp. 224-238, 6 February 2001.	
	AG	Ruef et al., "New antithrombotic drugs on the horizon", Expert Opin. Investig. Drugs, Vol. 12, No. 5, pp. 781-797, 2003.	
	AH	Wang et al., "Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats", Stroke, pp. 468-474, February 2003.	×
	Al	Weitz et al., "Thrombophilia and New Anticoagulant Drugs", Hematology, pp. 424-438, 2004.	
	AJ	Wong et al., "Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits", Vol. 303, No. 3, pp. 993-1000, 2002.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant